Clinical Trial Search

Primary: Progression-Free Survival Per BICR — 5.06; 4.17; 5.55; 4.90 months

Primary: Number of Participants With Postoperative Urinary Retention — 14; 16 Participants

Primary: The Proportion of Patients Who Die or Have Bleeding of WHO Grade 2 or Above by WHO Criteria During the First 30 Days From the First Dose of Trial Treatment, or Planned…

Primary: Mean Change in FEV1 (L) From Baseline to Week 48 — -0.186; -0.090 liters — p=0.7310

Primary: Frequency of Adverse Events — 69; 60; 62; 1 Number of adverse events

Primary: Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI — 3.79; 2.26; 3.48; 3.01 mean of a score (on a scale) per patient — p=< 0.0001

Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 50; 45; 3; 5 Participants

Primary: Substudy Analysis Cohorts — 18; 21; 25; 21 Participants

Primary: Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale — 188; 207; 16; 114…

Primary: Change in Cough Severity — 13.15; 9.54 LCQ scores (baseline to 3 months)

Primary: Number of Participants With CRoff at Week 36 — 8; 2 Participants

Primary: Percentage of Participants With Seroconversion for Anti-poliovirus Types 1, 2 and 3 Neutralizing Antibody (Ab) — 99.2; 99.3; 100; 99.3 Percentage of participants

Primary: Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS) — 5.55; 5.36 months — p=0.3504

Primary: Fold Change From Baseline at Week 24 in Pulmonary Vascular Resistance Index (PVRI) — 59.43 Fold change (percentage)

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -2.19; -1.75; -2.03; -0.77 percentage of HbA1c — p=<0.001